ING Group’s Royalty Pharma RPRX Stock Holding History

ING Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-114,600	Closed	-$2.92M	–	586
2024 Q4	$2.92M	Buy	+114,600	New	+$3.04M	0.02%	355
2024 Q3	–	Sell	-36,500	Closed	-$963K	–	599
2024 Q2	$963K	Hold	36,500	–	–	0.01%	497
2024 Q1	$1.11M	Sell	36,500 -9,700	-21%	-$286K	0.01%	499
2023 Q4	$1.3M	Buy	+46,200	New	+$1.27M	0.01%	461

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ING Group's RPRX Position: Q1 2025 in Review

ING Group sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 114,600 shares — an estimated $2.92M sold.

ING Group first reported a position in RPRX in Q4 2023 and held it in 4 quarters. The position peaked at $2.92M in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

ING Group reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
ING Group sold 114,600 Royalty Pharma shares in Q1 2025, an estimated $2.92M.
ING Group first reported a position in Royalty Pharma in Q4 2023 and held it in 4 quarters.
ING Group's Royalty Pharma position peaked at $2.92M in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on ING Group's 13F filing for Q1 2025, filed 9 May 2025.